Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study

Ítems similars

• A multicentre prospective cohort study assessing the effectiveness of budesonide MMX® (Cortiment®(MMX®)) for active, mild-to-moderate ulcerative colitis
  per: Danese, Silvio, et al.
  Publicat: (2019)
• Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study
  per: Travis, Simon P L, et al.
  Publicat: (2014)
• Induction of clinical and colonoscopic remission of mild–to–moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies
  per: Sandborn, W. J., et al.
  Publicat: (2015)
• Budesonide MMX for the Induction of Remission of Mild to Moderate Ulcerative Colitis: A Pooled Safety Analysis
  per: Lichtenstein, Gary R., et al.
  Publicat: (2015)
• Comparative assessment of budesonide‐MMX and mesalamine in active, mild‐to‐moderate ulcerative colitis: A systematic review and network meta‐analysis
  per: Bonovas, Stefanos, et al.
  Publicat: (2019)